Compare Lamb Weston Holdings Inc (LW) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Novavax Inc — how do they compare? Lamb Weston Holdings Inc trades at $53.16 (market cap $7.23B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Lamb Weston Holdings Inc is far larger — about 5.5× Novavax Inc's market cap, and Lamb Weston Holdings Inc pays a 2.89% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| LW | NVAX | |
|---|---|---|
Market Cap | $7.23B | $1.31B |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $11.19 |
52-Week Low | $38.48 | $6.22 |
Enterprise Value | $11.10B | $889.30M |
Dividend Yield | 2.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $53.04, up 2.37% today, near its consensus price target of $53.86. The stock shows a bullish technical trend with consistent earnings beats in recent quarters, including Q2 2026 EPS of $0.87 versus $0.626 expected. Revenue reached $6.45 billion in 2025, though net income margin declined to 4.39%. Analyst sentiment is mixed with 31.58% buy ratings, while institutional investors like Dimensional Fund Advisors increased holdings by 28.1% in Q1 2026 (SEC filing, 2026-07-29).
The outlook is cautiously optimistic given operational improvements and cost savings, but risks include international demand pressures and elevated costs. The stock offers a 3.1% dividend yield, with fiscal 2027 guidance projecting 1%-2% sales growth. Further upside depends on sustaining North American volume growth and margin stabilization amid macroeconomic headwinds.
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
